Bibliography
- Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52
- Scheller J, Garbers C, Rose-John S. Interleukin-6:from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12
- Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett 2011;585:3699-709
- Okuda O, Yoshida N, Maini RN. Methods for treating interleukin-6 related diseases. US2015010554 (A1); 2015
- Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther 2014;8:349-64
- Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6
- Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54(9):2817-29
- Ruderman EM. The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis. Bull Hosp Jt Dis 2013;71:S29-32
- Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50
- Bykerk VP, Ostor AJK, Alvaro-Gracia J, et al. Comparison of tocilizumab as monotherapy or with add-on disease-modiyfying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clin Rheumatol 2015;34:563-71
- Graudal N, Hubeck-Graudal T, Tarp S. Christensen R, jurgens G. Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized-controlled trials. PLoS One 2014;9:e106408
- Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011;50:552-62
- Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 2012;34:788-802